•  
  •  
 

Corresponding Author

Mahmoud Samy Saad El-Nahas

Document Type

Original Article

Abstract

Background: The initial tumour's histology is the most crucial determinant of prognosis for thyroid cancer. Papillary and follicular thyroid cancers are thyroid tumours originating from follicular cells and accounting for 90% of all thyroid cancers. The prognosis of papillary thyroid carcinoma is generally favourable, with a death rate of 1-2% during a 20-year period.

Aim and objectives: To assess the role of radioactive iodine ablation after total thyroidectomy in low-risk papillary thyroid cancer. The secondary objective is to assess the toxicity of Radioiodine.

Subjects and methods: The present work was prospective research of 30 individuals diagnosed with papillary thyroid cancer who presented to the General Surgery department, AL-Hussein University Hospital and Damanhur Medical National Institute from July 2022 to July 2023.

Results: Both groups had a significant variance regarding thyroglobulin at 12 months. There was a significant variance among four, eight, and 12 months regarding thyroglobulin in the radioiodine group. There were significant variances among both groups regarding Post TSH. There was significant variance in each group group among Pre TSH and TSH.

Conclusion: This research concluded that there was no significant variance among Radioiodine and non-radioiodine groups regarding response to Treatment at 4-8 Months and 1 Year. This suggests that non-radioiodine therapy has the same effect as radioiodine therapy after total thyroidectomy in individuals with low papillary thyroid cancer.

Keywords

Thyroid Cancer; Papillary Thyroid Carcinoma, Thyroidectomy

Subject Area

General Surgery

Download

Share

COinS